ArticleRedox biology2026
Acidic bile salts induce APE1-dependent PRDX2 activation to drive oxaliplatin resistance via ferroptosis inhibition.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of esophageal adenocarcinoma (EAC) is rapidly increasing in Western countries. Gastroesophageal reflux, containing acidic bile salts (ABS), is the main risk factor for EAC. Cancer cells develop adaptive abilities to recalibrate redox balance via hijacking the antioxidant systems to maintain reactive oxygen species (ROS) below lethal levels. We investigated the role of PRDX2 and its regulation in EAC chemoresistance under reflux conditions.
methodsWe analyzed public databases to identify PRDX2's aberrant overexpression and potential role in chemoresistance in EAC. To model acute and chronic GERD in vitro, we applied transient and repeated ABS exposures. Using 2D and 3D organotypic culture models of EAC cells, we investigated PRDX2's anti-ferroptosis, pro-chemoresistance functions, and regulatory mechanisms. In addition, we also utilized patient derived organoids and xenografts, cell line-derived xenografts, and human EAC tissue microarrays.
resultsAberrant expression of PRDX2 was detected in both human EAC tissues and cell lines under ABS exposure. PRDX2 was regulated via an APE1-redox-dependent transcription activation of NF-kB. The knockdown of PRDX2 impaired the recovery of EAC cells from ABS-induced ROS and ROS-dependent lipid peroxidation. Silencing PRDX2 sensitized the chemo-resistant EAC cells to oxaliplatin by enhancing ferroptosis. Mechanistically, we found that PRDX2 inhibits ferroptosis by stabilizing GPX4, a crucial ferroptosis suppressor. PRDX2 enhances GPX4 stability through OTUB1-dependent deubiquitination, preventing its degradation. The APE1-redox inhibitor APX2009 significantly sensitized EAC cells to oxaliplatin by downregulating PRDX2 and inducing ferroptosis. Importantly, the combination of oxaliplatin and APX2009 showed synergistic tumor-suppressive effects in xenograft models.
conclusionsOur findings revealed a novel link between reflux-induced redox rebalance and ferroptosis-related chemoresistance in EAC via APE1-redox/NF-kB/PRDX2/OUTB1/GPX4 signaling cascade. Targeting redox with APE1-redox-specific inhibitors is a potential novel strategy for drug combination in refractory EAC, via inhibition of PRDX2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.